
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1086 | 1043 | 1083 | 1300 | 1565 | 2297 |
Fund Return | 8.56% | 4.26% | 8.33% | 9.13% | 9.38% | 8.67% |
Place in category | 163 | 357 | 366 | 41 | 57 | 110 |
% in Category | 14 | 35 | 38 | 4 | 11 | 34 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
AXA Framlington Global Technology a | 1.17B | 3.22 | 10.42 | 19.08 | ||
AXA Framlington Global Technology F | 1.17B | 3.22 | 10.42 | 19.08 | ||
GB00B5LXGG05 | 1.11B | 3.82 | 15.38 | 16.74 | ||
AXA Global Distribution R Acc | 264.11M | 5.74 | -1.26 | 4.97 | ||
AXA Global Distribution R Inc | 264.11M | 7.05 | -0.84 | 5.18 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Janus Global Life Sciences Fund U G | 3.95B | 6.94 | 10.61 | 10.46 | ||
Wellington Global Health Care EquiG | 1.98B | 6.70 | 4.03 | 11.14 | ||
Adamant Medtech I GBP | 1.65B | 10.05 | 7.78 | 12.87 | ||
Global Health Care Fund W Acc GBP | 107.06M | 7.87 | 5.51 | 9.11 | ||
Pharmaceuticals Index Trust F Acc | 268.55K | 7.73 | 7.29 | 9.38 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Eli Lilly | US5324571083 | 8.65 | 929.72 | +2.05% | |
Merck&Co | US58933Y1055 | 5.27 | 93.19 | +0.68% | |
Novo Nordisk B | DK0062498333 | 5.22 | 631.5 | +2.48% | |
UnitedHealth | US91324P1021 | 4.82 | 475.98 | +0.29% | |
Thermo Fisher Scientific | US8835561023 | 4.53 | 524.19 | +1.48% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Strong Sell | Sell | Neutral |
Technical Indicators | Sell | Strong Sell | Strong Sell |
Summary | Strong Sell | Strong Sell | Sell |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review